Search Results - "Linde, Peter G."

Sotatercept for the Treatment of Pulmonary Arterial Hypertension by Humbert, Marc, McLaughlin, Vallerie, Gibbs, J. Simon R, Gomberg-Maitland, Mardi, Hoeper, Marius M, Preston, Ioana R, Souza, Rogerio, Waxman, Aaron, Escribano Subias, Pilar, Feldman, Jeremy, Meyer, Gisela, Montani, David, Olsson, Karen M, Manimaran, Solaiappan, Barnes, Jennifer, Linde, Peter G, de Oliveira Pena, Janethe, Badesch, David B

“…Patients with pulmonary arterial hypertension were randomly assigned to receive sotatercept at a dose of 0.3 mg per kilogram or 0.7 mg per kilogram or placebo,…”
Get full text

Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl by Chin, Melanie P., PhD, Wrolstad, Danielle, MS, Bakris, George L., MD, Chertow, Glenn M., MD, MPH, de Zeeuw, Dick, MD, PhD, Goldsberry, Angie, MS, Linde, Peter G., MD, McCullough, Peter A., MD, MPH, McMurray, John J., MD, Wittes, Janet, PhD, Meyer, Colin J., MD

“…Abstract Background A phase 3 randomized clinical trial was designed to test whether bardoxolone methyl, a nuclear factor erythroid-2–related factor 2 (Nrf2)…”
Get full text

Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes by Chen, Nianhang, Kassir, Nastya, Laadem, Abderrahmane, Maxwell, Stephen E., Sriraman, Priya, Giuseppi, Ana Carolina, Ritland, Steve, Linde, Peter G., Budda, Balasubrahmanyam, Reynolds, Joseph G., Zhou, Simon, Palmisano, Maria

“…Luspatercept is a recombinant fusion protein that enhances late‐stage erythroid maturation. This report describes the population pharmacokinetics and…”
Get full text

Comparison of Paricalcitol With Maxacalcitol Injection in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism by Akizawa, Tadao, Akiba, Takashi, Hirakata, Hideki, Kinugasa, Eriko, Tominaga, Yoshihiro, Fukagawa, Masafumi, Yokoyama, Keitaro, Zhang, Wuyan, Linde, Peter G., Suzuki, Masashi

“…Secondary hyperparathyroidism (SHPT) is one of the major complications of chronic kidney disease (CKD) and is associated with elevated serum intact parathyroid…”
Get full text

Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis by Siwy, Justyna, Zürbig, Petra, Argiles, Angel, Beige, Joachim, Haubitz, Marion, Jankowski, Joachim, Julian, Bruce A, Linde, Peter G, Marx, David, Mischak, Harald, Mullen, William, Novak, Jan, Ortiz, Alberto, Persson, Frederik, Pontillo, Claudia, Rossing, Peter, Rupprecht, Harald, Schanstra, Joost P, Vlahou, Antonia, Vanholder, Raymond

“…In spite of its invasive nature and risks, kidney biopsy is currently required for precise diagnosis of many chronic kidney diseases (CKDs). Here, we explored…”
Get full text

Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl by Chin, Melanie P, Reisman, Scott A, Bakris, George L, O'Grady, Megan, Linde, Peter G, McCullough, Peter A, Packham, David, Vaziri, Nosratola D, Ward, Keith W, Warnock, David G, Meyer, Colin J

“…Bardoxolone methyl, an Nrf2-activating and nuclear factor-κB-inhibiting semisynthetic oleanane triterpenoid compound, was evaluated in a phase 3 trial (BEACON)…”
Get more information

Population Pharmacokinetics and Exposure‐Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β‐Thalassemia by Chen, Nianhang, Kassir, Nastya, Laadem, Abderrahmane, Giuseppi, Ana Carolina, Shetty, Jeevan, Maxwell, Stephen E., Sriraman, Priya, Ritland, Steve, Linde, Peter G., Budda, Balasubrahmanyam, Reynolds, Joseph G., Zhou, Simon, Palmisano, Maria

“…β‐Thalassemia is an inherited blood disorder resulting from defects in hemoglobin production, leading to premature death of red blood cells (RBCs) or their…”
Get full text

Overcoming Barriers in Kidney Health-Forging a Platform for Innovation by Linde, Peter G, Archdeacon, Patrick, Breyer, Matthew D, Ibrahim, Tod, Inrig, Jula K, Kewalramani, Reshma, Lee, Celeste Castillo, Neuland, Carolyn Y, Roy-Chaudhury, Prabir, Sloand, James A, Meyer, Rachel, Smith, Kimberly A, Snook, Jennifer, West, Melissa, Falk, Ronald J

“…Innovation in kidney diseases is not commensurate with the effect of these diseases on human health and mortality or innovation in other key therapeutic areas…”
Get full text

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes by Fenaux, Pierre, Platzbecker, Uwe, Mufti, Ghulam J, Garcia-Manero, Guillermo, Buckstein, Rena, Santini, Valeria, Díez-Campelo, María, Finelli, Carlo, Cazzola, Mario, Ilhan, Osman, Sekeres, Mikkael A, Falantes, José F, Arrizabalaga, Beatriz, Salvi, Flavia, Giai, Valentina, Vyas, Paresh, Bowen, David, Selleslag, Dominik, DeZern, Amy E, Jurcic, Joseph G, Germing, Ulrich, Götze, Katharina S, Quesnel, Bruno, Beyne-Rauzy, Odile, Cluzeau, Thomas, Voso, Maria-Teresa, Mazure, Dominiek, Vellenga, Edo, Greenberg, Peter L, Hellström-Lindberg, Eva, Zeidan, Amer M, Adès, Lionel, Verma, Amit, Savona, Michael R, Laadem, Abderrahmane, Benzohra, Aziz, Zhang, Jennie, Rampersad, Anita, Dunshee, Diana R, Linde, Peter G, Sherman, Matthew L, Komrokji, Rami S, List, Alan F

“…Luspatercept is a fusion protein aimed at binding TGF-β family members and reducing SMAD2 and SMAD3 signaling in patients with myelodysplasia with ring…”
Get full text

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia by Cappellini, M. Domenica, Viprakasit, Vip, Taher, Ali T, Georgiev, Pencho, Kuo, Kevin H.M, Coates, Thomas, Voskaridou, Ersi, Liew, Hong-Keng, Pazgal-Kobrowski, Idit, Forni, G.L, Perrotta, Silverio, Khelif, Abderrahim, Lal, Ashutosh, Kattamis, Antonis, Vlachaki, Efthymia, Origa, Raffaella, Aydinok, Yesim, Bejaoui, Mohamed, Ho, P. Joy, Chew, Lee-Ping, Bee, Ping-Chong, Lim, Soo-Min, Lu, Meng-Yao, Tantiworawit, Adisak, Ganeva, Penka, Gercheva, Liana, Shah, Farrukh, Neufeld, Ellis J, Thompson, Alexis, Laadem, Abderrahmane, Shetty, Jeevan K, Zou, Jun, Zhang, Jennie, Miteva, Dimana, Zinger, Tatiana, Linde, Peter G, Sherman, Matthew L, Hermine, Olivier, Porter, John, Piga, Antonio

“…Patients with transfusion-dependent β-thalassemia were randomly assigned to receive luspatercept (a binder for TGF-β family member ligands) or placebo. During…”
Get full text

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial by Porter, John, Cappellini, Maria Domenica, Coates, Thomas, Hermine, Olivier, Viprakasit, Vip, Voskaridou, Ersi, Liew, Hong Keng, Perrotta, Silverio, Khelif, Abderrahim, Kattamis, Antonis, Laadem, Abderrahmane, Shetty, Jeevan K., Kuo, Wen-Ling, Miteva, Dimana, Zinger, Tatiana, Linde, Peter G., Sinsimer, Daniel, Taher, Ali

“…Introduction: BELIEVE is an ongoing phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of luspatercept, a…”
Get full text

A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia with or without RBC transfusion dependence by Mesa, Ruben A., Barosi, Giovanni, Harrison, Claire N., Kiladjian, Jean-Jacques, Gale, Robert Peter, Laadem, Abderrahmane, Gerike, Torsten, Linde, Peter G., Sherman, Matthew L., Pariseau, Joseph, Verstovsek, Srdan

“…Abstract only…”
Get full text

Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS) by Komrokji, Rami S., Sekeres, Mikkael A., Zeidan, Amer Methqal, Fenaux, Pierre, List, Alan F., Dezern, Amy Elizabeth, Greenberg, Peter L., Savona, Michael R., Jurcic, Joseph G., Verma, Amit, Mufti, Ghulam J., Buckstein, Rena, Santini, Valeria, Laadem, Abderrahmane, Ito, Rodrigo, Zhang, Jennie, Louis, Chrystal Ursula, Linde, Peter G., Garcia-Manero, Guillermo

“…Abstract only 7518 Background: MEDALIST (NCT02631070) is a randomized, placebo (PBO)-controlled, phase 3 trial evaluating the efficacy and safety of…”
Get full text

Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study by Zeidan, Amer Methqal, Garcia-Manero, Guillermo, Dezern, Amy Elizabeth, Fenaux, Pierre, Greenberg, Peter L., Savona, Michael R., Jurcic, Joseph G., Verma, Amit, Mufti, Ghulam J., Buckstein, Rena, Santini, Valeria, Laadem, Abderrahmane, Zhang, Jennie, Rampersad, Anita, Sinsimer, Daniel, Louis, Chrystal Ursula, Linde, Peter G., List, Alan F., Sekeres, Mikkael A.

“…Abstract only 7554 Background: Anemic pts with LR-MDS and high baseline RBC transfusion burden (HTB) have very few treatment options and constitute a pt…”
Get full text

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial by Platzbecker, Uwe, Dunshee, Diana, Komrokji, Rami S., Mufti, Ghulam J., Garcia-Manero, Guillermo, Buckstein, Rena, Santini, Valeria, Díez-Campelo, María, Sekeres, Mikkael A., See, Wendy L., Tsai, Kevin, Risueño, Alberto, Ma, Jianglin, Schwickart, Martin, Rampersad, Anita, Zhang, Jennie, Laadem, Abderrahmane, Menezes, Daniel, MacBeth, Kyle, Linde, Peter G., Reynolds, Joseph G., List, Alan F., Fenaux, Pierre

“…Background: Luspatercept is a first-in-class erythroid maturation agent that binds TGF-β superfamily ligands to reduce aberrant Smad2/3 signaling and enhance…”
Get full text

A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia by Gerds, Aaron T., Vannucchi, Alessandro M., Passamonti, Francesco, Kremyanskaya, Marina, Gotlib, Jason R., Palmer, Jeanne M., McCaul, Kelly, Ribrag, Vincent, Mead, Adam J., Harrison, Claire N, Mesa, Ruben A, Kiladjian, Jean-Jacques, Barosi, Giovanni, Gale, Robert Peter, Laadem, Abderrahmane, Pariseau, Joseph, Gerike, Torsten, Zhang, Jennie, Linde, Peter G., Reynolds, Joseph G., Verstovsek, Srdan

“…Introduction: Approximately two-thirds of patients with primary or post-essential thrombocythemia/polycythemia vera myelofibrosis (MF) have anemia, many of…”
Get full text

Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions by Viprakasit, Vip, Taher, Ali, Hermine, Olivier, Porter, John, Piga, Antonio, Kuo, Kevin H.M., Coates, Thomas, Voskaridou, Ersi, Liew, Hong Keng, Perrotta, Silverio, Khelif, Abderrahim, Kattamis, Antonis, Laadem, Abderrahmane, Shetty, Jeevan K., Kuo, Wen-Ling, Miteva, Dimana, Zinger, Tatiana, Sinsimer, Daniel, Linde, Peter G., Cappellini, Maria Domenica

“…Introduction: β-thalassemia is an inherited hemoglobinopathy characterized by ineffective erythropoiesis and anemia. Luspatercept is a first-in-class erythroid…”
Get full text

Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions by Garcia-Manero, Guillermo, Mufti, Ghulam J., Fenaux, Pierre, Buckstein, Rena, Santini, Valeria, Díez-Campelo, María, Finelli, Carlo, Cazzola, Mario, Ilhan, Osman, Sekeres, Mikkael A., List, Alan F., Laadem, Abderrahmane, Ito, Rodrigo, Zhang, Jennie, Rampersad, Anita, Sinsimer, Daniel, Linde, Peter G., Platzbecker, Uwe, Komrokji, Rami

“…Introduction: Lower-risk MDS is characterized by anemia and ineffective erythropoiesis leading to RBC transfusion dependence. Effective treatment for anemia…”
Get full text

Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions by Fenaux, Pierre, Mufti, Ghulam J., Buckstein, Rena, Santini, Valeria, Díez-Campelo, María, Finelli, Carlo, Cazzola, Mario, Ilhan, Osman, Sekeres, Mikkael A., Komrokji, Rami S., List, Alan F., Zeidan, Amer M., Verma, Amit, Laadem, Abderrahmane, Ito, Rodrigo, Zhang, Jennie, Rampersad, Anita, Sinsimer, Daniel, Linde, Peter G., Garcia-Manero, Guillermo, Platzbecker, Uwe

“…Introduction: Few treatment options are available to RBC transfusion-dependent pts with lower-risk MDS (LR-MDS) who are refractory/ineligible for…”
Get full text

Erythropoietic cellular analyses in luspatercept-treated lower-risk myelodysplastic syndromes (MDS): Phase 2 PACE-MDS study by Platzbecker, Uwe, Giagounidis, Aristoteles, Kiewe, Philipp M., Germing, Ulrich, Gotze, Katharina S., Mayer, Karin, Radsak, Markus, Wolff, Thomas, Chromik, Jörg, Reynolds, Joseph, Barron, Carolyn, Rovaldi, Chris, Suragani, Rajasekhar NVS, Zhang, Xiaosha, Laadem, Abderrahmane, Linde, Peter G., Sherman, Matthew L., Oelschlägel, Uta

“…Abstract only…”
Get full text